Literature DB >> 17253887

Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients.

Hao Chen1, Chenghong Peng, Zhicheng Yu, Baiyong Shen, Xiaxing Deng, Weihua Qiu, Yue Fei, Chuan Shen, Guangwen Zhou, Weiping Yang, Hongwei Li.   

Abstract

OBJECTIVES: This study aimed to: (i) define the clinical pharmacokinetics of mycophenolic acid (MPA) in Chinese liver transplant recipients; and (ii) develop a regression model best fitted for the prediction of MPA area under the plasma concentration-time curve from 0 to 12 hours (AUC(12)) by abbreviated sampling strategy.
METHODS: Forty liver transplant patients received mycophenolate mofetil 1g as a single dose twice daily in combination with tacrolimus. MPA concentrations were determined by high-performance liquid chromatography before dose (C(0)) and at 0.5 (C(0.5)), 1 (C(1)), 1.5 (C(1.5)), 2 (C(2)), 4 (C(4)), 6 (C(6)), 8 (C(8)), 10 (C(10)) and 12 (C(12)) hours after administration on days 7 and 14. A total of 72 pharmacokinetic profiles were obtained. MPA AUC(12) was calculated with 3P97 software. The trough concentrations (C(0)) of tacrolimus and hepatic function were also measured simultaneously. Multiple linear regression analysis was used to establish the models for estimated MPA AUC(12). The agreement between predicted MPA AUC(12) and observed MPA AUC(12) was investigated by Bland-Altman analysis.
RESULTS: The pattern of MPA concentrations during the 12-hour interval on day 7 was very similar to that on day 14. In the total of 72 profiles, the mean maximum plasma concentration (C(max)) and time to reach C(max) (t(max)) were 9.79 +/- 5.26 mg/L and 1.43 +/- 0.78 hours, respectively. The mean MPA AUC(12) was 46.50 +/- 17.42 mg . h/L (range 17.99-98.73 mg . h/L). Correlation between MPA C(0) and MPA AUC(12) was poor (r(2) = 0.300, p = 0.0001). The best model for prediction of MPA AUC(12) was by using 1, 2, 6 and 8 hour timepoint MPA concentrations (r(2) = 0.921, p = 0.0001). The regression equation for estimated MPA AUC(12) was 5.503 + 0.919 . C(1) + 1.871 . C(2) + 3.176 . C(6) + 3.664 . C(8). This model had minimal mean prediction error (1.24 +/- 11.19%) and minimal mean absolute prediction error (8.24 +/- 7.61%). Sixty-three of 72 (88%) estimated MPA AUC(12) were within 15% of MPA AUC(12). Bland-Altman analysis also revealed the best agreement of this model compared with the others and a mean error of +/-9.89 mg . h/mL.
CONCLUSION: This study showed the wide variability in MPA AUC(12) in Chinese liver transplant recipients. Single timepoint MPA concentration during the 12-hour dosing interval cannot reflect MPA AUC(12). MPA AUC(12) could be predicted accurately using 1, 2, 6 and 8 hour timepoint MPA concentrations by abbreviated sampling strategy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17253887     DOI: 10.2165/00003088-200746020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Determination of mycophenolate area under the curve by limited sampling strategy.

Authors:  S Yeung; K L Tong; W K Tsang; H L Tang; K S Fung; H W Chan; A Y Chan; L Chan
Journal:  Transplant Proc       Date:  2001 Feb-Mar       Impact factor: 1.066

Review 2.  Immunosuppressant drugs--the role of therapeutic drug monitoring.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  2001       Impact factor: 4.335

Review 3.  Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients.

Authors:  L M Shaw; M Korecka; D DeNofrio; K L Brayman
Journal:  Clin Biochem       Date:  2001-02       Impact factor: 3.281

Review 4.  Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

Authors:  M Oellerich; M Shipkova; E Schütz; E Wieland; L Weber; B Tönshoff; V W Armstrong
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

Review 5.  Pharmacokinetics of mycophenolate mofetil (RS61443): a short review.

Authors:  R E Bullingham; A Nicholls; M Hale
Journal:  Transplant Proc       Date:  1996-04       Impact factor: 1.066

6.  Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus.

Authors:  A Jain; R Venkataramanan; I S Hamad; S Zuckerman; S Zhang; J Lever; V S Warty; J J Fung
Journal:  J Clin Pharmacol       Date:  2001-03       Impact factor: 3.126

7.  Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil.

Authors:  M Mourad; J Malaise; D Chaib Eddour; M De Meyer; J König; R Schepers; J P Squifflet; P Wallemacq
Journal:  Clin Chem       Date:  2001-01       Impact factor: 8.327

8.  Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction.

Authors:  Marcelo Cantarovich; George N Tzimas; J Barkun; M Deschênes; E Alpert; J Tchervenkov
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

9.  Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range.

Authors:  John Michael Tredger; Nigel William Brown; Jemimah Adams; Chris Elton Gonde; Anil Dhawan; Mohamed Rela; Nigel Heaton
Journal:  Liver Transpl       Date:  2004-04       Impact factor: 5.799

Review 10.  Mycophenolate mofetil in solid-organ transplantation.

Authors:  Titte R Srinivas; Bruce Kaplan; Herwig Ulf Meier-Kriesche
Journal:  Expert Opin Pharmacother       Date:  2003-12       Impact factor: 3.889

View more
  6 in total

Review 1.  Clinical mycophenolic acid monitoring in liver transplant recipients.

Authors:  Hao Chen; Bing Chen
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  The occurrence of diarrhea not related to the pharmacokinetics of MPA and its metabolites in liver transplant patients.

Authors:  Zhang Wei Xia; Chen Yong Jun; Chen Hao; Chen Bing; Shi Min Min; Xie Jun Jie
Journal:  Eur J Clin Pharmacol       Date:  2010-05-15       Impact factor: 2.953

3.  Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.

Authors:  Noël Zahr; Zahir Amoura; Jean Debord; Jean-Sébastien Hulot; Franck Saint-Marcoux; Pierre Marquet; Jean Charles Piette; Philippe Lechat
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

4.  Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients.

Authors:  Talia Mazidi; Mohammad-Reza Rouini; Mohammad-Hossein Ghahremani; Simin Dashti-Khavidaki; Mahboob Lessan-Pezeshki; Farrokh Lagha Ahmadi; Jamshid Salam-Zadeh; Ali Mandegary; Kheirollah Gholami
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

5.  A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration-Time Curve Estimation.

Authors:  Joanna Sobiak; Matylda Resztak
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-09-04       Impact factor: 2.441

6.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.